Lymphoma

Lymphoma is the most common hematologic malignancy. Despite the relative success of chemotherapy and radiotherapy for this kind of disease, some patients are either resistant to first-line therapy or relapse after initial treatment. At Alfa Cytology, we have dedicated to unraveling the complexities of this disease, driven by a relentless pursuit of innovative solutions.

Introduction to Lymphoma

Lymphoma is a complex and heterogeneous group of cancers that affect the lymphatic system, a critical part of the body's immune system. It arises from the uncontrolled proliferation of lymphocytes, a type of white blood cell found in the lymph nodes, spleen, bone marrow, and other lymphoid tissues.

Fig.1 Cytology of Hodgkin lymphoma.

Lymphoma is broadly classified into two main categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). These two types differ in terms of their characteristics, behavior, and treatment approaches.

Therapeutic Strategies Development for Lymphoma

The global lymphoma treatment market was valued at USD 7.7 billion in 2021 and is expected to reach USD 15.8 billion by 2030, growing at a CAGR of 8.4% from 2022-2030. Increase in the number of lymphoma cases is the major factor driving the value growth of the global lymphoma treatment market. In addition, increasing involvement of major players in R&D has led to increasing product lines, which is also a major trend in the lymphoma treatment market.

• Currently, Celgene has filed applications for three drugs, fludarabine, cyclophosphamide and JCAR017, for the treatment of patients with non-Hodgkin's lymphoma. patients with non-Hodgkin's lymphoma. All three drugs are in Phase 2 clinical trials.
• In addition, Genmab A/S, in collaboration with AbbVie, has filed a patent application for a drug called Epcoritamab. It is indicated for the treatment of diffuse large B-cell lymphoma and primary mediastinal lymphoma.

Our Services

This surge in market size underscores the increasing demand for effective and innovative therapy solutions. At Alfa Cytology, with a team of highly skilled and experienced biological experts who have worked in the industry for many years, our company understands the unique challenges associated with lymphoma therapy and is committed to providing cutting-edge solutions. Our expertise allows us to provide lymphoma diagnostics development and innovative therapy development to pharmaceutical companies worldwide.

For more information about our lymphoma research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us at Alfa Cytology. Our dedicated team of experts is committed to collaborating with healthcare providers and research institutions to drive progress in the fight against lymphoma.

For research use only.